相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Shannon L. Reynolds et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2017)
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation
Steven Deitelzweig et al.
Journal of Managed Care & Specialty Pharmacy (2017)
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
Adrienne M. Gilligan et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2017)
Prevalence and Geographic Variations of Polypharmacy Among West Virginia Medicaid Beneficiaries
Xue Feng et al.
ANNALS OF PHARMACOTHERAPY (2017)
Impact of a Guideline for the Management of Antimicrobial/Warfarin Interactions in the Inpatient Setting and Across Transition of Care
Nghi B. Ha et al.
ANNALS OF PHARMACOTHERAPY (2016)
Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States
Tim Bancroft et al.
CLINICAL THERAPEUTICS (2016)
Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation
Kevin Francis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Hospital Costs Associated With Atrial Fibrillation for Patients With Ischemic Stroke Aged 18-64 Years in the United States
Guijing Wang et al.
STROKE (2015)
Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines
Siobhan Dumbreck et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines
Siobhan Dumbreck et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Craig T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
T. Lanitis et al.
JOURNAL OF MEDICAL ECONOMICS (2014)
Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Doug Coyle et al.
VALUE IN HEALTH (2013)
Concurrent Use of Warfarin and Antibiotics and the Risk of Bleeding in Older Adults
Jacques Baillargeon et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
Edith Nutescu et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
A New Era for Anticoagulation in Atrial Fibrillation
Jessica L. Mega
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The role of thrombin and protease-activated receptors in pain mechanisms
Paul S. Garcia et al.
THROMBOSIS AND HAEMOSTASIS (2010)
The impact of atrial fibrillation on the cost of stroke:: The Berlin acute stroke study
Bernd Brueggenjuergen et al.
VALUE IN HEALTH (2007)
分享论文
